Table of Contents
J. Clin. Med., Volume 7, Issue 7 (July 2018)
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) Despite significant investments into antibiotic discovery in the past, no new antibiotic class with [...] Read more. Despite significant investments into antibiotic discovery in the past, no new antibiotic class with novel mode(s) of action against Pseudomonas aeruginosa has been approved in half a century. The reasons for this failure have been identified and are caused by low outer membrane permeability and extensive efflux. To overcome these challenges tobramycin-linked efflux pump inhibitor conjugates (TOB-EPI) have been designed as adjuvants. TOB-EPI conjugates are capable of enhancing antimicrobial potency and/or restoring microbiologicial efficacy in select antibiotics including fluoroquinolones, rifampicin and fosfomycin against a panel of multi drug-resistant P. aeruginosa isolates. TOB-EPI conjugates are believed to interfere with the bacterial membranes thereby enhancing the intracellular concentration of the primary antibiotic. View this paper